Agios Pharm

NASDAQ AGIO

Data sourced from

and

Download Data

Agios Pharm Interest Expense To Sales 1 year YoY Change (%) for the year ending December 31, 2022: -95.55%

Agios Pharm Interest Expense To Sales 1 year YoY Change (%) is -95.55% for the year ending December 31, 2022, a -100.42% change year over year. The interest expense to sales ratio is a financial metric that represents the proportion of a company's revenue that is used to cover its interest expenses. It is calculated by dividing the company's interest expense by its total revenue. This ratio indicates the financial burden of interest payments on the company's operating income. A higher ratio suggests that a significant portion of the company's revenue is being used to service interest obligations, potentially affecting its profitability. The measure "Change (%)" refers to the percentage change in the value of a financial metric between two time points. This measure provides a relative perspective on the magnitude of change.

Agios Pharm Interest Expense To Sales for the year ending December 31, 2022 was 89.84%, a -95.55% change year over year.
Agios Pharm Interest Expense To Sales for the year ending December 31, 2021 was 2,018.88%, a 22,905.23% change year over year.
Agios Pharm Interest Expense To Sales for the year ending December 31, 2020 was 8.78%, a -30.37% change year over year.
Agios Pharm Interest Expense To Sales for the year ending December 31, 2019 was 12.60%, a -27.69% change year over year.

NASDAQ: AGIO

Agios Pharm

CEO	Dr. Bruce D. Car DACVP, Ph.D.
IPO Date	July 24, 2013
Location	United States
Headquarters	88 Sidney Street, Cambridge, MA, United States, 02139-4169
Employees	383
Sector	Healthcare
Industry	Biotechnology

Description

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Key trends